VJHemOnc Podcast
By VJHemOnc
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by VJHemOnc
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 1
Reviews: 0
Episodes: 237
Description
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
| Episode | Date |
|---|---|
|
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
|
Apr 26, 2024 |
|
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
|
Apr 11, 2024 |
|
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
|
Apr 04, 2024 |
|
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
|
Mar 28, 2024 |
|
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
|
Mar 22, 2024 |
|
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
|
Mar 15, 2024 |
|
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
|
Mar 07, 2024 |
|
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
|
Feb 29, 2024 |
|
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
|
Feb 22, 2024 |
|
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
|
Feb 16, 2024 |
|
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
|
Feb 08, 2024 |
|
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
|
Jan 31, 2024 |
|
Updates, challenges and novel agents being explored in BPDCN
|
Jan 25, 2024 |
|
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
|
Jan 18, 2024 |
|
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
|
Jan 12, 2024 |
|
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
|
Jan 05, 2024 |
|
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
|
Dec 22, 2023 |
|
iwNHL 2023 Session V: Expanding the CAR platform in NHL
|
Dec 15, 2023 |
|
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
|
Dec 07, 2023 |
|
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
|
Dec 01, 2023 |
|
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
|
Nov 24, 2023 |
|
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
|
Nov 17, 2023 |
|
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
|
Nov 10, 2023 |
|
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
|
Nov 03, 2023 |
|
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
|
Oct 27, 2023 |
|
iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes
|
Oct 20, 2023 |
|
Classifying frailty and approaching elderly patients with lymphoma
|
Oct 13, 2023 |
|
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
|
Oct 06, 2023 |
|
iwAL 2023 Session III: The relevance of TP53 mutation in AML
|
Sep 29, 2023 |
|
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
|
Sep 22, 2023 |
|
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
|
Sep 15, 2023 |
|
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
|
Sep 08, 2023 |
|
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
|
Aug 23, 2023 |
|
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
|
Aug 16, 2023 |
|
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
|
Aug 10, 2023 |
|
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
|
Aug 03, 2023 |
|
Overcoming barriers to CAR-T therapy: improving access and cost
|
Jul 27, 2023 |
|
The importance of addressing quality of life and improving symptom management in MPNs
|
Jul 19, 2023 |
|
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
|
Jul 11, 2023 |
|
Hemophilia: the current standard of care and the value of novel gene therapies
|
Jul 05, 2023 |
|
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
|
Jun 29, 2023 |
|
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
|
Jun 22, 2023 |
|
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
|
Jun 16, 2023 |
|
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
|
Jun 07, 2023 |
|
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
|
May 31, 2023 |
|
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
|
May 24, 2023 |
|
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
|
May 18, 2023 |
|
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
|
May 11, 2023 |
|
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
|
May 02, 2023 |
|
The current role of stem cell transplantation in MPNs & how this may change with novel agents
|
Apr 27, 2023 |
|
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
|
Apr 19, 2023 |
|
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
|
Apr 12, 2023 |
|
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
|
Apr 05, 2023 |
|
Insights into the changing role of chemotherapy in lymphoma
|
Mar 31, 2023 |
|
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
|
Mar 24, 2023 |
|
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
|
Mar 16, 2023 |
|
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
|
Mar 10, 2023 |
|
The current status of CAR-T therapy in CLL and challenges in this space
|
Mar 03, 2023 |
|
Managing and treating GvHD and other post-transplant complications
|
Feb 23, 2023 |
|
The role of MRD in multiple myeloma
|
Feb 14, 2023 |
|
Novel immune therapies in MDS and challenges in this space
|
Feb 07, 2023 |
|
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies
|
Feb 02, 2023 |
|
MPN highlights at ASH 2022: novel agents, combinations & the role of immunotherapy
|
Jan 26, 2023 |
|
T-cell lymphoma highlights at ASH 2022: unmet needs, clinical trial updates & future outlooks
|
Jan 20, 2023 |
|
The importance of CD47 in MDS and other targets of interest
|
Jan 17, 2023 |
|
CLL highlights at ASH 2022: clinical trial updates, novel BTK inhibitors & combination therapy
|
Jan 09, 2023 |
|
Myeloma highlights at ASH 2022: improving access to CAR-T therapy & future outlooks
|
Jan 03, 2023 |
|
Highlights in MDS at ASH 2022: treating lower-risk & higher-risk disease, trial updates, & more
|
Dec 21, 2022 |
|
iwNHL Session V: novel therapies in NHL – the role of ADCs
|
Dec 16, 2022 |
|
iwAL 2022 Session V: mechanisms of resistance to targeted therapies in AML
|
Dec 06, 2022 |
|
The importance of genomic testing in CLL and its role in clinical decision-making
|
Dec 02, 2022 |
|
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
|
Nov 30, 2022 |
|
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
|
Nov 25, 2022 |
|
iwAL 2022 Session IV: the evolving treatment landscape in ALL and the growing role of immunotherapies
|
Nov 22, 2022 |
|
iwNHL Session III: exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
|
Nov 18, 2022 |
|
iwAL 2022 Session III: novel targets, combinations and treatment strategies in AML
|
Nov 16, 2022 |
|
Recent updates in CML: treatment strategies, clinical trials, and novel agents
|
Nov 11, 2022 |
|
iwNHL Session II: understanding and harnessing the immune microenvironment against lymphoma
|
Nov 09, 2022 |
|
iwAL 2022 Session II: novel treatment strategies in ALL
|
Nov 04, 2022 |
|
The role of the innate immune system in MDS
|
Nov 02, 2022 |
|
iwAL 2022 Session I: the standard of care in AML in 2022
|
Oct 28, 2022 |
|
iwNHL 2022 Session I: advances in the treatment of T-cell lymphoma
|
Oct 26, 2022 |
|
ISA 2022: meeting highlights and recent updates in amyloidosis
|
Oct 21, 2022 |
|
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
|
Oct 13, 2022 |
|
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
|
Oct 07, 2022 |
|
iwMDS 2022: Key highlights
|
Sep 29, 2022 |
|
Identifying high-risk myeloma and improving treatment strategies in these patients
|
Sep 22, 2022 |
|
Improving the efficiency of drug approvals in MDS
|
Sep 14, 2022 |
|
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
|
Sep 09, 2022 |
|
The need for more effective first-line therapies in MDS
|
Sep 07, 2022 |
|
Myeloma 2022: day two highlights
|
Sep 02, 2022 |
|
The promise of CAR-T therapy in CLL and challenges in the field
|
Aug 31, 2022 |
|
Clonal hematopoiesis and pre-MDS states
|
Aug 24, 2022 |
|
T-cell engagers in multiple myeloma: current challenges and future outlooks
|
Aug 24, 2022 |
|
High-risk MDS: unmet needs and future treatment approaches
|
Aug 19, 2022 |
|
The importance of patient-reported outcomes in CAR-T recipients
|
Aug 17, 2022 |
|
CAR-T therapy in myeloma and lymphoma
|
Aug 12, 2022 |
|
CAR-T therapy in AML: challenges and future outlooks
|
Aug 10, 2022 |
|
The current state of CAR-T therapy in lymphoma
|
Aug 05, 2022 |
|
Myeloma treatment updates from EHA 2022
|
Aug 03, 2022 |
|
Updates in classification and risk stratification in MDS
|
Jul 27, 2022 |
|
Myeloma 2022: day one highlights
|
Jul 27, 2022 |
|
Immune dysregulation and targeting in MDS
|
Jul 22, 2022 |
|
The future of CAR-T therapy in ALL
|
Jul 20, 2022 |
|
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
|
Jul 15, 2022 |
|
Key updates in the treatment and management of MPNs
|
Jul 08, 2022 |
|
Addressing unmet needs and future treatment approaches in AL amyloidosis
|
Jul 01, 2022 |
|
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
|
Jun 24, 2022 |
|
Updates in lymphoma and CLL treatment in the UK
|
Jun 17, 2022 |
|
The importance of early interception and intervention in myeloma
|
Jun 07, 2022 |
|
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
|
Jun 03, 2022 |
|
CAR-T and lymphoma treatment in the UK
|
May 27, 2022 |
|
Harnessing the power of immunotherapy in myeloma and amyloidosis
|
May 20, 2022 |
|
The impact of AI and machine learning algorithms in MDS
|
May 13, 2022 |
|
MMRF-CoMMpass: the genomic basis of myeloma subtypes
|
May 06, 2022 |
|
Genomics in the age of immuno-oncology
|
Apr 29, 2022 |
|
Understanding multiple myeloma at the single-cell level
|
Apr 22, 2022 |
|
Recent advances in amyloidosis treatment
|
Apr 01, 2022 |
|
ASH 2021: a deep dive into ALL immunotherapy
|
Mar 25, 2022 |
|
ASH 2021: what did ASH 2021 mean for MDS?
|
Mar 18, 2022 |
|
ASH 2021: novel developments in MPNs
|
Mar 11, 2022 |
|
ASH 2021: evaluating the impact of screening for MGUS and SMM
|
Mar 04, 2022 |
|
ASH 2021: the future of cell therapies in lymphoma
|
Feb 25, 2022 |
|
ASH 2021: highlights in CLL clinical trials
|
Feb 18, 2022 |
|
ASH 2021: updates in FLT3 mutated AML
|
Feb 11, 2022 |
|
The Lymphoma Sessions: post-ASH 2021
|
Feb 02, 2022 |
|
COSTEM: maintenance therapies for FLT3+ AML
|
Oct 25, 2021 |
|
COSTEM: the role of alloHSCT in ALL
|
Oct 25, 2021 |
|
SOHO 2021: amyloidosis treatment updates
|
Sep 30, 2021 |
|
IACH 2021: CAR-T in clinical practice
|
Sep 30, 2021 |
|
Unmet needs and recent updates in CML
|
Sep 29, 2021 |
|
IMW 2021: treatment-free intervals in multiple myeloma
|
Sep 29, 2021 |
|
Highlights from iwCLL 2021
|
Sep 27, 2021 |
|
IMW 2021: MRD in myeloma
|
Sep 20, 2021 |
|
CAR-T vs bispecifics: replacing ASCT in myeloma
|
Sep 17, 2021 |
|
EHA 2021: antibody therapies for NHL
|
Sep 10, 2021 |
|
EHA 2021: updates on novel agents for AML
|
Sep 08, 2021 |
|
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
|
Sep 03, 2021 |
|
EHA 2021: targeted therapies for ALL
|
Sep 01, 2021 |
|
Texas MPN Workshop 2021: updates on interferons for MPNs
|
Aug 27, 2021 |
|
EHA 2021: real-world data on myeloma, lymphoma and CLL
|
Aug 25, 2021 |
|
Novel BTK inhibitors for NHL
|
Aug 19, 2021 |
|
Latest updates on T-cell therapies for non-Hodgkin lymphoma
|
Aug 18, 2021 |
|
Novel CD20/CD3 bispecific antibodies in NHL
|
Aug 17, 2021 |
|
Latest updates on CAR-T therapy for lymphoma
|
Aug 16, 2021 |
|
EHA & ICML 2021: updates in Hodgkin lymphoma
|
Aug 06, 2021 |
|
Latest transplant updates from EHA 2021
|
Aug 04, 2021 |
|
Key updates on CAR-T therapy for multiple myeloma
|
Aug 02, 2021 |
|
The Lymphoma Sessions: highlights from EHA and ICML 2021
|
Jul 30, 2021 |
|
The CLL Sessions: highlights from EHA and ICML 2021
|
Jul 27, 2021 |
|
EHA 2021: updates on treatment for MDS
|
Jul 26, 2021 |
|
iwNHL 2021: immunotherapy and the microenvironment
|
Jul 23, 2021 |
|
The Myeloma Sessions: key highlights from EHA and ASCO 2021
|
Jul 21, 2021 |
|
EHA 2021: key trial updates in myelofibrosis
|
Jul 20, 2021 |
|
The MPN Sessions: highlights from EHA and ASCO 2021
|
Jul 16, 2021 |
|
The MDS Sessions: highlights from ASCO/EHA 2021
|
Jul 08, 2021 |
|
EHA 2021: fixed-duration therapies and sequencing in CLL
|
Jul 08, 2021 |
|
The AML Sessions: Highlights from ASCO/EHA 2021
|
Jul 07, 2021 |
|
EHA 2021: key trial updates in myeloma
|
Jul 07, 2021 |
|
Key updates on CAR-T therapy for ALL
|
Jul 05, 2021 |
|
The Myeloma Sessions: post-COMy 2021 myeloma patients session
|
Jun 28, 2021 |
|
EHA 2021: MRD in myeloma
|
Jun 25, 2021 |
|
Latest updates on CAR-T therapy for CLL
|
Jun 16, 2021 |
|
The Myeloma Sessions: post-COMy 2021 roundtable
|
Jun 03, 2021 |
|
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
|
May 28, 2021 |
|
MDS Session: Women in Science
|
May 17, 2021 |
|
Key updates on CAR-T & cellular therapy for AML
|
May 17, 2021 |
|
The MDS Sessions: highlights from ASH 2020
|
Apr 27, 2021 |
|
The Transplant Sessions: ASH 2020 highlights
|
Apr 23, 2021 |
|
The Lymphoma Sessions: ASH 2020 highlights
|
Apr 23, 2021 |
|
Latest updates in Hodgkin lymphoma from ISHL HL 2021
|
Apr 20, 2021 |
|
The Myeloma Sessions: Post-ASH 2020 UK Discussion
|
Apr 19, 2021 |
|
The Post-EBMT for Trainees VJSessions
|
Apr 15, 2021 |
|
Post-ASH Amyloidosis Session from VJHemOnc
|
Apr 13, 2021 |
|
The Post-EBMT VJSessions from VJHemOnc
|
Apr 07, 2021 |
|
Post-EBMT highlights in acute myeloid leukemia
|
Apr 06, 2021 |
|
The CLL Sessions: highlights from ASH 2020
|
Mar 17, 2021 |
|
The Lymphoma Sessions: highlights from ASH 2020
|
Mar 17, 2021 |
|
The MDS Sessions: Giants in MDS
|
Mar 17, 2021 |
|
Latest therapies in AML: IMGN632, magrolimab & gilteritinib
|
Mar 16, 2021 |
|
VJSession: EBMT/EHA CAR-T Nursing Session
|
Feb 23, 2021 |
|
The Myeloma Sessions: key updates from ASH 2020
|
Feb 22, 2021 |
|
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
|
Feb 19, 2021 |
|
Updates for the management of MDS from ASH 2020
|
Feb 16, 2021 |
|
The AML Sessions: highlights from ASH 2020
|
Feb 16, 2021 |
|
The MDS Sessions: treating MDS around the world
|
Feb 12, 2021 |
|
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
|
Feb 05, 2021 |
|
Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020
|
Jan 28, 2021 |
|
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
|
Jan 20, 2021 |
|
Advances in CAR T-cell therapies for lymphoma from ASH 2020
|
Jan 18, 2021 |
|
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
|
Jan 11, 2021 |
|
The MDS sessions: lower-risk disease
|
Dec 07, 2020 |
|
The AML Sessions: FLT3-mutated disease
|
Nov 27, 2020 |
|
The Lymphoma Sessions: highlights from iwNHL 2020
|
Nov 18, 2020 |
|
The MDS sessions: clinical trial participation, endpoints & approvals
|
Nov 17, 2020 |
|
The AML Sessions: Venetoclax-based regimens
|
Nov 12, 2020 |
|
The AML Sessions: IDH inhibitors
|
Nov 03, 2020 |
|
The AML Sessions: Immunotherapy
|
Oct 08, 2020 |
|
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
|
Oct 01, 2020 |
|
SOHO 2020: Next questions in hematological malignancies
|
Sep 25, 2020 |
|
The MPN Sessions: pathobiology, therapeutic strategies & clinical trials
|
Sep 15, 2020 |
|
Latest AML therapies: novel preparations and first in class agents
|
Sep 14, 2020 |
|
Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells
|
Sep 10, 2020 |
|
CLL: MRD and first-in class agents
|
Aug 13, 2020 |
|
The Myeloma Sessions: Evolving management of myeloma & COVID-19
|
Aug 06, 2020 |
|
MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls
|
Aug 06, 2020 |
|
The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies
|
Jul 31, 2020 |
|
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
|
Jul 28, 2020 |
|
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
|
Jul 16, 2020 |
|
Key updates in ALL at EHA 2020
|
Jul 07, 2020 |
|
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
|
Jul 03, 2020 |
|
Systemic mastocytosis: current landscape, novel agents and COVID-19
|
Jun 02, 2020 |
|
MRD assessment in AML: incorporation into clinical practice
|
Apr 22, 2020 |
|
Myeloma management in the COVID-19 era
|
Apr 14, 2020 |
|
CAR-T in the CLL space
|
Apr 02, 2020 |
|
CAR T-cell therapy & multiple myeloma: past, present & future
|
Apr 02, 2020 |
|
Harnessing the tumor microenvironment in lymphoma therapy
|
Apr 02, 2020 |
|
CLL therapy: the latest trial updates and innovative novel therapies for the future
|
Sep 20, 2019 |
|
Precision epigenetic therapy for B-cell lymphoma
|
Jul 18, 2019 |
|
Induction therapy in myeloma: an ever-changing paradigm
|
Jul 18, 2019 |
|
iwAL 2019: looking to the future of acute leukemia therapy
|
Jun 06, 2019 |
|
Acute leukemia: pushing boundaries in disease management
|
Jun 06, 2019 |
|
CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma
|
Dec 18, 2018 |
|
MRD testing in multiple myeloma: new technology with promising clinical applications
|
Nov 23, 2018 |
|
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
|
Oct 11, 2018 |
|
Patient discussion at EHA 2018: CAR T-cells and MRD in CLL
|
Sep 14, 2018 |
|
CLL therapies today: novel agents, combinations & the future of the field
|
Aug 20, 2018 |
|
CAR T-cell therapy: where are we now and what’s in store for the future?
|
Jul 25, 2018 |
|
Focus on MRD: current landscape and future questions in hemonc
|
Jul 04, 2018 |
|
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
|
Mar 16, 2018 |
|
Acute leukemias: is MRD already a surrogate for survival?
|
Mar 09, 2018 |
|
Revolutionary immunotherapies for lymphoma
|
Feb 02, 2018 |
|
Latest advances and current challenges in immunotherapies for lymphoma
|
Dec 15, 2017 |
|
The circle of CLL: from gene discovery to targeted treatment
|
Dec 08, 2017 |
|
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
|
Nov 16, 2017 |
|
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
|
Nov 16, 2017 |
|
Debate on the use of MRD for multiple myeloma management
|
Nov 16, 2017 |